Newsletter Signup | Community
IMpassion130 clinical trial: The checkpoint inhibitor Tecentriq improves outcomes of Triple Negative Breast Cancer
Checkpoint PD-1 inhibitors and Sacituzumab Govitecan (IMMU-132) promising treatment for triple negative breast cancer
Drs. From Scripps believe that Targaprimir-96 could be the next TNBC treatment?
Obesity Linked with Triple-Negative Breast Cancer
Triple Negative Breast Cancer Linked with Higher Rate of Distant Metastases.
Novel Precision Medicine Promising in Triple-Negative Breast Cancer.
Iniparib Promising in Metastatic Triple-negative Breast Cancer
Dr. Bhuvaneswari Ramaswamy of the OSU Arthur G. James Cancer Hospital answers frequently asked questions about TNBC
Erbitux May Increase Response Rates in Metastatic Triple-Negative Breast Cancer.
Interesting data published this week show HDC appears to benefit TNBC:
